Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Closes $40M Round of Financing

NEW YORK (GenomeWeb News) – BG Medicine said today that it has raised $40 million in a Series D financing.
 
The privately held molecular diagnostics firm said the funding would enable it to complete development and commercialization of its first two diagnostic products and continue discovery and development of additional product candidates.
 
Investors in the round included Legg Mason Capital Management, GE Asset Management, and Smallcap World Fund. They joined current investors Flagship Ventures, Glide Healthcare Partners, Humana, and Stelios Papadopoulos.
 
Leerink Swann acted as placement agent for the financing.
 
Waltham, Mass.-based BG last year filed for an initial public offering on the Euronext Amsterdam Exchange. However, the firm withdrew the offering earlier this year, citing “current market conditions.”
 

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.